GENERAL2 Oct 2026
Exclusive: Eli Lilly CEO David Ricks on M&A, AI and the search for the next big drug - CNBC TV18
Eli Lilly's CEO David Ricks told CNBC-TV18 that the drugmaker wants to buy more companies, sees risk in its growing consumer exposure, and worries most about a lack of breakthrough inventions. He also spoke about Lilly's India manufacturing and technology plans, how artificial intelligence (AI) helps drug discovery, and which treatment areas may see future breakthroughs.
Key Statutory Highlights
- Eli Lilly CEO David Ricks said the drugmaker plans to become more acquisitive.
- He flagged risks from the company's growing consumer exposure.
- Ricks said a lack of breakthrough inventions is Lilly's biggest long-term concern.
Actionable Advice for Taxpayers / Founders:If you deal with Eli Lilly or track pharma, follow the company's official announcements and regulatory filings before acting on any deal or expansion news, and check with a registered adviser before making business or investment decisions.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: